E. Laker

发表

An Interactive Voice Response Software to Improve the Quality of Life of People Living With HIV in Uganda: Randomized Controlled Trial (Preprint)

R. King, B. Castelnuovo, A. Kiragga, 2020 .

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

P. Easterbrook, H. Namata, A. Siika, 2018, The Lancet. Infectious diseases.

An Interactive Voice Response Software to Improve the Quality of Life of People Living With HIV in Uganda: Randomized Controlled Trial

R. King, B. Castelnuovo, A. Kiragga, 2021, JMIR mHealth and uHealth.

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala

A. Kiragga, R. Parkes-Ratanshi, I. Mambule, 2014, Journal of the International AIDS Society.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

P. Easterbrook, T. Peto, N. French, 2017, The lancet. HIV.

The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women

K. Seden, B. Castelnuovo, A. Kiragga, 2020, Drug Safety.

Symptomatic cerebrospinal fluid HIV-1 escape in two patients on second-line antiretroviral therapy in Uganda

N. Nakasujja, A. Calcagno, M. Lamorde, 2019, Oxford medical case reports.

Dolutegravir-associated hyperglycaemia in patients with HIV.

B. Castelnuovo, A. Kiragga, M. Lamorde, 2020, The lancet. HIV.

Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B

D. Boulware, K. H. Hullsiek, R. Mannino, 2020, Antimicrobial Agents and Chemotherapy.

Safety and tolerability of a novel oral formulation of amphotericin B: Phase I EnACT Trial 1

D. Boulware, K. H. Hullsiek, R. Mannino, 2020 .

Impact of community engagement and social support on the outcomes of HIV-related meningitis clinical trials in a resource-limited setting

L. Haddow, S. Lofgren, D. Boulware, 2020, Research Involvement and Engagement.

Symptomatic Cryptococcal Antigenemia Presenting as Early Cryptococcal Meningitis With Negative Cerebral Spinal Fluid Analysis.

S. Lofgren, D. Boulware, K. H. Hullsiek, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV-Associated Cryptococcal Meningitis Occurring at Relatively Higher CD4 Counts

S. Lofgren, D. Boulware, K. H. Hullsiek, 2018, The Journal of infectious diseases.

High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily

K. Seden, S. Khoo, M. Lamorde, 2018, The Journal of antimicrobial chemotherapy.

Prevalence of overweight and obesity and associated factors among people living with HIV attending a tertiary care clinic in Uganda

F. Bongomin, M. Nabaggala, Theresa Piloya, 2022, BMC Nutrition.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

The burden of drug resistant tuberculosis in a predominantly nomadic population in Uganda: a mixed methods study

W. Worodria, A. Katamba, J. Kalyango, 2021, BMC Infectious Diseases.

Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial.

Takudzwa J Mtisi, S. Jaffar, D. Boulware, 2022, The Lancet. Global health.

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

P. Easterbrook, N. French, H. Namata, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence and type of drug‐drug interactions involving antiretrovirals in patients attending a specialist outpatient clinic in Kampala, Uganda

K. Seden, D. Back, C. Merry, 2012 .

Prevalence and type of drug–drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda

K. Seden, S. Khoo, D. Back, 2015, The Journal of antimicrobial chemotherapy.

Factors associated with uptake of contraceptives among HIV positive women on dolutegravir based anti-retroviral treatment-a cross sectional survey in urban Uganda

S. Okoboi, S. Kiwanuka, B. Castelnuovo, 2022, BMC Women's Health.

Factors Associated with Uptake of Contraceptives among HIV Positive Women on Dolutegravir based Anti-Retroviral Treatment at Health Centres of Kampala Capital City Authority. A cross sectional study in Uganda.

S. Okoboi, S. Kiwanuka, B. Castelnuovo, 2021 .

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir

B. Castelnuovo, A. Kiragga, M. Lamorde, 2019, BMC Infectious Diseases.

Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B

D. Boulware, K. H. Hullsiek, R. Mannino, 2020, Antimicrobial Agents and Chemotherapy.

Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks

R. Bollinger, J. Schwarz, B. Castelnuovo, 2023, Research square.

Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks

R. Bollinger, N. Brusselaers, R. Kiguba, 2023, Research square.

Factors associated with uptake of contraceptives among HIV positive women on dolutegravir based anti-retroviral treatment-a cross sectional survey in urban Uganda

S. Okoboi, S. Kiwanuka, B. Castelnuovo, 2021, BMC Women's Health.